Paul Hales

Statistics

Publications

Citations

H-Index

Active since

1987

Affiliations

Millennium Engineering and Integration (United States)(Current)

Takeda (United States)

University of Alberta

Queen's Medical Centre

Medicines for Malaria Venture

Paul Hales is an author at Millennium Engineering and Integration (United States) specializing in life sciences, pharmacology, and proteasome inhibitors.

ORCID

Publications per year

1987–2021

Publications

Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase

Chad Vickers, Paul Hales, Virendar K. Kaushik et al. · Journal of Biological Chemistry · 2002 · 1.4K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

Erik Kupperman, Edmund C. Lee, Yueying Cao et al. · Cancer Research · 2010 · 493 citations

Medicine, Oncology, Pharmacology +13

Substrate-Based Design of the First Class of Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors

Natalie A. Dales, Alexandra E. Gould, James A. Brown et al. · Journal of the American Chemical Society · 2002 · 187 citations · Full text

Life Sciences, Biochemistry, Pharmacology +13

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

Christopher Blackburn, Kenneth M. Gigstad, Paul Hales et al. · Biochemical Journal · 2010 · 146 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +14

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

Edmund C. Lee, Michael Fitzgerald, Bret Bannerman et al. · Clinical Cancer Research · 2011 · 106 citations

Medicine, Oncology, Pharmacology +16

1–5 of 21